News

August 14, 2019

Progenics Enters Collaboration with Veterans Affairs for Medical Image Analysis

News

Progenics Pharmaceuticals has entered a collaboration with Veteran Affairs Greater Los Angeles Healthcare System (VAGLAHS) to support the development of new machine learning tools aimed at improving detection of prostate ... Read more

August 12, 2019September 4, 2019

Breast, Ovarian Cancer Therapy Seen to Delay to Progression in Advanced Prostate Cancers in Phase 3 Trial

News

Men with metastatic castration-resistant prostate cancer (mCRPC) given Lynparza (olaparib), a breast and ovarian cancer treatment, went a clinically meaningful longer time without disease progression or death compared to those given standard ... Read more

August 8, 2019September 10, 2019

First Patients Dosed in Phase 2b Trial Testing Oral Docetaxel Treatment for Advanced Prostate Cancer

News

A Phase 2b clinical trial evaluating ModraDoc006/r, Modra Pharmaceutical’s investigational oral treatment for metastatic castration-resistant prostate cancer, has started dosing patients, the company announced. ModraDoc006/r is a tablet formulation of the ... Read more

August 7, 2019August 26, 2019

Prostate Cancer Therapy Zytiga Makes WHO’s Essential Medicines List

News

Zytiga (abiraterone acetate), a kind of hormone therapy, has been added to the World Health Organization’s (WHO) Essential Medicines List for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Updated every ... Read more

August 5, 2019

Xtandi Delays Disease Worsening in Metastatic Hormone-sensitive Prostate Cancer, Study Says

News

Adding Xtandi (enzalutamide) to androgen deprivation therapy (ADT) significantly delays disease progression or death in men with metastatic hormone-sensitive prostate cancer (mHSPC), regardless of how spread the disease is, a Phase 3 ... Read more

August 1, 2019September 9, 2019

FDA Approves Nubeqa Tablets for Men with Non-metastatic Castration-resistant Prostate Cancer

News

The U.S. Food and Drug Administration (FDA) has approved Nubeqa (darolutamide) tablets to treat men with non-metastatic castration-resistant prostate cancer (nmCRPC). “We know that men with nmCRPC are still in ... Read more

July 31, 2019July 31, 2019

Invitae Offers Free Genetic Testing, Counseling for Hereditary Prostate Cancer

News

Invitae has launched a free genetic testing program to help connect prostate cancer patients to earlier diagnosis and treatments. The program also offers eligible patients free genetic counseling to help ... Read more

July 29, 2019July 29, 2019

ADT Linked to Higher Alzheimer’s and Dementia Risk in Older Prostate Cancer Patients, Study Suggests

News

Men with prostate cancer who undergo treatment with androgen deprivation therapy (ADT) — a form of hormone therapy that aims to slow disease progression by reducing the levels of male ... Read more

July 25, 2019

PyL Imaging Agent Ably Detects Lesions Outside the Prostate, Phase 2/3 Trial Shows

News

PyL, a new imaging agent for positron emission topography (PET) scans, can accurately detect prostate cancer lesions outside the prostate, whether in nearby lymph nodes or in distant locations, clinical ... Read more

July 24, 2019

Video Series Tackles Prostate Cancer and ADT Use in Doctor-Patient Format

News

CURE Media Group has introduced a video discussion series on topics of concern to prostate cancer patients, including cardiovascular risk management and androgen deprivation therapy (ADT). Called “ADT in Prostate Cancer: ... Read more